FDA-Approved Medications for Neuropathy
Only four medications are FDA-approved specifically for neuropathic pain: pregabalin, duloxetine, tapentadol extended-release, and capsaicin 8% patch 1, 2. Additionally, lidocaine 5% patches and gabapentin have FDA approval for specific neuropathic conditions 3.
Specific FDA Approvals by Condition
For Painful Diabetic Peripheral Neuropathy (DPN):
- Duloxetine (oral SSNRI)
- Pregabalin (oral gabapentinoid)
- Tapentadol extended-release (oral opioid)
- Capsaicin 8% topical system 1, 2
For Postherpetic Neuralgia (PHN):
- Pregabalin (oral gabapentinoid)
- Gabapentin (oral gabapentinoid)
- Lidocaine 5% patches (topical)
- Capsaicin 8% patch 3, 4
For Both DPN and PHN:
Pregabalin is the only agent FDA-approved for both painful diabetic neuropathy and postherpetic neuralgia 3.
Critical Distinctions
It is essential to understand that many commonly prescribed medications for neuropathic pain—including tricyclic antidepressants, venlafaxine, and standard gabapentin formulations for most neuropathic conditions—are NOT FDA-approved for neuropathic pain but are used off-label based on guideline recommendations 2, 5.
Device-Based FDA Approvals
Several spinal cord stimulation (SCS) devices have recently received FDA approval specifically for refractory painful diabetic neuropathy 2. This represents an important option when pharmacologic treatments fail.
Clinical Pitfalls
- Pregabalin's status has evolved: While FDA-approved and listed as first-line in international guidelines, more recent French guidelines (2020) downgraded it to second-line due to lower efficacy in recent studies and misuse risk 5
- Duloxetine's limitation: Despite FDA approval for DPN, duloxetine has not been studied in other neuropathic pain types, so its efficacy beyond DPN remains unknown 6
- Gabapentin approval specificity: Gabapentin is FDA-approved for postherpetic neuralgia specifically, not for all neuropathic pain conditions 3